Related Experiment Videos
Heparin regulates smooth muscle S phase entry in the injured rat carotid artery
Insights
Heparin inhibits smooth muscle cell proliferation after arterial injury. It acts late in cell cycle progression, not by preventing initial cell activation, to reduce growth.
Area of Science:
- Vascular biology
- Cell cycle regulation
- Pharmacology
Background:
- Smooth muscle cell (SMC) proliferation in injured arteries is a key factor in restenosis.
- The precise mechanism and timing of heparin's antiproliferative action on SMCs remain unclear.
- Understanding heparin's inhibitory site is crucial for developing targeted therapies.
Purpose of the Study:
- To determine the specific phase of the cell cycle at which heparin inhibits SMC proliferation following arterial injury.
- To investigate the temporal relationship between SMC activation and heparin's antiproliferative effect.
Main Methods:
- Rat carotid artery injury model was used.
- Ornithine decarboxylase (ODC) activity induction served as a marker for SMC cell cycle entry.
- [3H]thymidine incorporation was used to assess DNA synthesis and SMC proliferation.
- Heparin administration was varied in timing relative to the injury.
Main Results:
- ODC activity rapidly increased within 6 hours post-injury, indicating prompt SMC activation.
- Heparin did not inhibit ODC induction, suggesting it doesn't block initial cell cycle entry.
- Heparin significantly reduced [3H]thymidine-labelled SMC nuclei at 33 hours post-injury.
- Delayed heparin administration (up to 18 hours) retained significant antiproliferative effects, but later delays diminished efficacy.
Conclusions:
- SMCs rapidly exit quiescence and enter the cell cycle after arterial injury.
- Heparin exerts its antiproliferative effect late in the prereplicative (G1) phase or early in the S phase of the cell cycle.
- These findings elucidate the mechanism of heparin's action, targeting later stages of SMC activation.
Abstract:
Smooth muscle cell (SMC) proliferation in injured arteries is inhibited by heparin, but the mechanism of inhibition is unknown. In particular, it is not clear whether heparin prevents exit of quiescent SMC from the resting state, inhibits progression through the prereplicative (G1) sequence, or acts during DNA synthesis itself. In this study, induction of ornithine decarboxylase (ODC) activity was used as a marker of SMC entry into the cell cycle in an attempt to localize the site of heparin action during the initial hours after rat carotid injury. Rapid and transient induction of ODC activity was observed that reached a maximum (twenty-three-fold) 6 hours after wounding. Heparin failed to prevent ODC induction but greatly reduced frequencies of [3H]thymidine-labelled SMC nuclei 33 hours after injury. Moreover, heparin infusion could be delayed for up to 18 hours after the injury event with no significant loss of antiproliferative effect. Further delays resulted in marked loss of growth inhibition. The results of these studies show that SMC rapidly and synchronously leave the resting state after injury and suggest that heparin acts late in the prereplicative (G1) sequence or early in S phase to inhibit SMC proliferation in damaged arteries.